Cello Health BioConsulting
  • menu
  • Home
  • About us
    • Why We’re Different
    • Our Team
    • Mission, Vision & Values
  • Capabilities
    • Common Client Dilemmas
    • Opportunity Assessments
    • Opportunity Search and Evaluation
    • Portfolio and Platform Strategy
    • Business Development & Partnering Strategy
    • Market Access Strategy
    • Early Stage Strategy
  • Our Insights
    • News
    • Presentations
    • Testimonials
    • Events
  • Careers
    • Current Opportunities
    • A Day in the Life
    • Our Culture
MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn’s Disease

MorphoSys Announces its Licensee Janssen has Initiated a Phase 2/3 Program (GALAXI) to Evaluate Tremfya(R) (Guselkumab) in Crohn’s Disease

View Article +
Nanobiotix Announces Positive Phase Ii/iii Topline Data In Soft Tissue Sarcoma With Nbtxr3

Nanobiotix Announces Positive Phase Ii/iii Topline Data In Soft Tissue Sarcoma With Nbtxr3

View Article +
Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting

Avadel to Present Late-Breaker Data and Product Theater Forum at the 2018 American Urological Association Annual Meeting

View Article +
Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

Nanobiotix presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting

View Article +
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3’s significant potential role in Immuno-Oncology at SITC Annual Meeting

View Article +
Boehringer, Dicerna pen $201M pact to hit NASH with RNAi

Boehringer, Dicerna pen $201M pact to hit NASH with RNAi

View Article +
Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer

Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer

View Article +
Medicines Co scores FDA OK for new antibiotic, now up on the auction block

Medicines Co scores FDA OK for new antibiotic, now up on the auction block

View Article +
FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis

FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis

View Article +
MorphoSys Celebrates 25th Anniversary

MorphoSys Celebrates 25th Anniversary

View Article +
  2. ←
  3. 1
  4. 2
  5. 3
  6. 4
  7. 5
  8. 6
  9. 7
  10. 8
  11. 9
  12. →

Search

Elsewhere

Let’s work together

Contact us

  • Cello Health BioConsulting
  • 25-B Hanover Road
  • Suite 320
  • Florham Park, NJ
  • 07932
  • USA
  • +1 973 292 5001
  •  
  • Part of Cello Health plc

    Follow us

    Cello Health BioConsulting

    ©2021 Defined Health, now known as Cello Health BioConsulting | Privacy policy.

    View Presentation

    View Presentation

    Please fill the form to access the presentation.
    • This field is for validation purposes and should be left unchanged.

    We are using cookies to give you the best experience on our website.

    You can find out more about which cookies we are using or switch them off in settings.

    Defined Health, now known as Cello Health BioConsulting
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

    Strictly Necessary Cookies

    Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

    If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

    3rd Party Cookies

    This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

    Keeping this cookie enabled helps us to improve our website.

    Please enable Strictly Necessary Cookies first so that we can save your preferences!